862 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Dow 30 Stock Roundup: Microsoft Buys Cloud Tech Firm, Disney's "Beauty and the Beast" http://www.zacks.com/stock/news/256420/dow-30-stock-roundup-microsoft-buys-cloud-tech-firm-disneys-beauty-and-the-beast?cid=CS-ZC-FT-256420 Apr 13, 2017 - The index experienced an eventful and holiday shortened week, marked by growing geopolitical tensions.
The IDO-Inhibitor Race Is On to Improve Cancer Treatment https://www.fool.com/investing/2017/04/13/the-ido-inhibitor-race-is-on-to-improve-cancer-tre.aspx?source=iedfolrf0000001 Apr 13, 2017 - NewLink Genetics and Incyte Corporation's IDO-inhibitors could be the next big advance in cancer treatment.
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops http://www.zacks.com/stock/news/256282/pharma-stock-roundup-merck-gets-crl-for-label-expansion-effort-roche-cancer-drug-tops?cid=CS-ZC-FT-256282 Apr 13, 2017 - Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo http://www.zacks.com/stock/news/256261/bristol-myers-bmy-collaborates-with-apexigen-for-opdivo?cid=CS-ZC-FT-256261 Apr 12, 2017 - Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.
Drug Shortages Push Up Prices of Similar Drugs https://www.wsj.com/articles/prescription-drug-shortages-help-push-up-prices-of-similar-drugs-1492030801?mod=pls_whats_news_us_business_f Apr 12, 2017 - Prescription-drug supply shortages have hurt U.S. medical care in recent years. According to new research, they’ve also caused another side effect—drug-price increases.
Inovio's Ebola Vaccine Positive in Expanded Phase I Study http://www.zacks.com/stock/news/256211/inovios-ebola-vaccine-positive-in-expanded-phase-i-study?cid=CS-ZC-FT-256211 Apr 12, 2017 - Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails http://www.zacks.com/stock/news/255888/mercks-bid-to-add-cardiovascular-data-on-januvia-label-fails?cid=CS-ZC-FT-255888 Apr 10, 2017 - Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Kite Pharma Completes Filing for CAR-T Therapy with FDA http://www.zacks.com/stock/news/254949/kite-pharma-completes-filing-for-car-t-therapy-with-fda?cid=CS-ZC-FT-254949 Apr 03, 2017 - Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion http://www.zacks.com/stock/news/254418/bristol-myers-bmy-opdivo-gets-positive-chmp-opinion?cid=CS-ZC-FT-254418 Mar 28, 2017 - Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma http://www.zacks.com/stock/news/254180/mercks-ketruda-gets-positive-chmp-opinion-for-lymphoma?cid=CS-ZC-FT-254180 Mar 27, 2017 - Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).
<<<Page 81>